New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 31, 2012
08:08 EDTCOVCovidien raises FY13 Phamaceutical unit sales growth guidance to up 3%-6%
Covidien announced that as a result of the FDA approval of its generic version of CONCERTA and continued good operational performance, Covidien is increasing the fiscal 2013 net sales guidance for the Pharmaceuticals segment to 3%-6% above 2012 from the previous range of 1%-4% above 2012. There are no other changes to Covidienís previously announced 2013 guidance, the company said, adding that more details will be provided on January 25, 2013, when the company announces its first-quarter results. Covidien announced in December 2011 that it plans to spin off its Pharmaceuticals segment, Mallinckrodt, into a stand-alone company, a process expected to be completed in mid-2013.
News For COV From The Last 14 Days
Check below for free stories on COV the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
09:23 EDTCOVBarclays medical supplies/devices analysts hold analyst/industry conference call
Subscribe for More Information
April 14, 2014
08:05 EDTCOVCovidien announces FDA 510(k) clearance for Kangaroo feeding tube
Subscribe for More Information
April 11, 2014
11:42 EDTCOVCovidien liability from recall appears limited, says Brean Capital
Subscribe for More Information
08:10 EDTCOVCovidien implements voluntary recall of devices
Subscribe for More Information
April 8, 2014
07:26 EDTCOVElsevier Business Intelligence to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use